A Phase 3 interventional study of Acalabrutinib and Ibrutinib in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 130 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 5th largest by enrollment, is one of 4 that started in 2015, is one of 9 in phase 3, reaches primary completion later than 1 of the 27 other live ones, and was the 4th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
Zulfa Omer · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Seema Bhat · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 9 · Phase 4 1
First in 2014; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 533 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 61 across the 39 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca: 6 open now, 21 under way, 5 of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 5th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2015, is one of 7 in phase 3, reaches primary completion later than 2 of the 20 other live ones, and was the 13th registered.
AstraZeneca’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2005.
9 of the studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT05971251University of Alabama at BirminghamAddition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | 2026-12-31 |
| NCT06757647Seema BhatAcalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 2026-12-31 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AstraZeneca’s 42 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have ≥ 1 of the following high-risk prognostic factors:
Meet the following laboratory parameters:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral acalabrutinib 100 mg twice daily (BID) until disease progression (PD), or unacceptable toxicity, or other reasons for discontinuation, whichever occurs first.
Drug: Acalabrutinib
Participants will receive oral ibrutinib 420 mg once daily (QD) until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurrs first.
Drug: Ibrutinib
Participants will receive oral acalabrutinib as stated in arm description.
Also known as: ACP-196
Participants will receive oral ibrutinib as stated in arm description.
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment
The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia \[iwCLL\] 2008 criteria): Lymphocytes \>= 50% increase over baseline, or \>= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or \>= 50% platelets or \> 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kaplan-Meier method.
Time frame: Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)
Number of Participants With Treatment-emergent Infections Grade >= 3
Number of participants with treatment-emergent infections Grade \>=3 are reported.
Time frame: Day 1 through 83.5 months (maximum observed duration)
Number of Participants With Treatment-emergent Richter's Transformation
Richter's transformation is defined as the occurrence of an aggressive lymphoma in participants with a previous or concomitant diagnosis of CLL. Richter's transformation was assessed by central pathology. Number of participants with treatment-emergent Richter's transformation are reported.
Time frame: Day 1 through 83.5 months (maximum observed duration)
Number of Participants With Treatment-emergent Atrial Fibrillation
Number of participants with treatment-emergent atrial fibrillation (including atrial flutter) are reported.
Time frame: Day 1 through 83.5 months (maximum observed duration)
Overall Survival (OS)
The OS is defined as the time from date of randomization to date of death due to any cause. The OS is assessed using the Kaplan-Meier method.
Time frame: Baseline (Days -28 to -1) through 83.7 months (maximum observed duration)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through 83.5 months (maximum observed duration)
Number of Participants With Treatment-emergent Laboratory Abnormalities
Number of participants with treatment-emergent laboratory abnormalities are reported. Laboratory abnormality is defined as any abnormal finding during analysis of hematology and serum chemistry.
Time frame: Day 1 through 83.5 months (maximum observed duration)
Number of Participants With Abnormal Vital Signs Reported as TEAEs
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, heart rate, and respiratory rate).
Time frame: Day 1 through 83.5 months (maximum observed duration)
Percentage of Participants With Lymphocytosis
Percentage of participants with at least one occurrence of treatment-related lymphocytosis defined as an elevation in ALC of \>= 50% compared with baseline and a postbaseline assessment of \> 5000/μL in the peripheral blood are reported.
Time frame: Day 1 through 83.5 months (maximum observed duration)
Number of Participants With Electrocardiogram (ECG) Abnormality at Baseline
Number of participants with ECG abnormality at baseline are reported.
Time frame: Baseline (Days -28 to -1)
Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
The ECOG performance status assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=death. Number of participants with shift from baseline (Days -28 to -1) to worst Grade 3 and 4 in ECOG performance status are reported.
Time frame: Baseline (Days -28 to -1) through 83.5 months (maximum observed duration)
| Milestone | Acalabrutinib | Ibrutinib |
|---|---|---|
| Started | 268 | 265 |
| Treated | 265 | 264 |
| Completed | 0 | 0 |
| Not completed | 268 | 265 |
| Withdrew: Death | 89 | 106 |
| Withdrew: Lost to follow-up | 7 | 5 |
| Withdrew: Withdrawal by subject | 37 | 34 |
| Withdrew: Physician decision | 7 | 9 |
| Withdrew: Study terminated by sponsor | 103 | 99 |
| Withdrew: Other reasons including transition to commercial drug | 23 | 12 |
| Withdrew: Missing/unknown | 2 | 0 |
The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia \[iwCLL\] 2008 criteria): Lymphocytes \>= 50% increase over baseline, or \>= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or \>= 50% platelets or \> 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kaplan-Meier method.
| Months | Acalabrutinib | Ibrutinib |
|---|---|---|
| Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment | 38.4 (33.0 to 38.6) | 38.4 (33.0 to 41.6) |
Number of participants with treatment-emergent infections Grade \>=3 are reported.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Number of Participants With Treatment-emergent Infections Grade >= 3 | 98 | 101 |
Richter's transformation is defined as the occurrence of an aggressive lymphoma in participants with a previous or concomitant diagnosis of CLL. Richter's transformation was assessed by central pathology. Number of participants with treatment-emergent Richter's transformation are reported.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Number of Participants With Treatment-emergent Richter's Transformation | 13 | 14 |
Number of participants with treatment-emergent atrial fibrillation (including atrial flutter) are reported.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Number of Participants With Treatment-emergent Atrial Fibrillation | 32 | 49 |
The OS is defined as the time from date of randomization to date of death due to any cause. The OS is assessed using the Kaplan-Meier method.
| Months | Acalabrutinib | Ibrutinib |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (65.0 to NA) |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Any TEAEs | 262 | 259 |
| Any TESAEs | 161 | 177 |
Number of participants with treatment-emergent laboratory abnormalities are reported. Laboratory abnormality is defined as any abnormal finding during analysis of hematology and serum chemistry.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Absolute neutrophil count (decreased) | 124 | 135 |
| Haemoglobin (decreased) | 139 | 131 |
| Platelets (decreased) | 119 | 116 |
| Leukocytes (decreased) | 60 | 64 |
| Leukocytes (increased) | 68 | 84 |
| Absolute lymphocyte count (ALC) (decreased) | 66 | 65 |
| ALC (increased) | 71 | 72 |
| Alanine aminotransferase (increased) | 73 | 70 |
| Albumin (decreased) | 31 | 44 |
| Alkaline phosphatase (increased) | 66 | 60 |
| Aspartate aminotransferase (increased) | 42 | 58 |
| Bilirubin (increased) | 46 | 69 |
| Calcium (decreased) | 56 | 71 |
| Calcium (increased) | 15 | 11 |
| Creatinine (increased) | 164 | 168 |
| Glucose (decreased) | 5 | 13 |
| Glucose (increased) | 21 | 23 |
| Phosphate (decreased) | 93 | 74 |
| Potassium (decreased) | 27 | 40 |
| Potassium (increased) | 62 | 52 |
| Sodium (decreased) | 26 | 37 |
| Sodium (increased) | 70 | 46 |
| Urate (increased) | 70 | 96 |
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, heart rate, and respiratory rate).
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Abnormal loss of weight | 0 | 1 |
| Blood pressure fluctuation | 0 | 1 |
| Blood pressure increased | 2 | 3 |
| Blood pressure decreased | 1 | 0 |
| Blood pressure systolic increased | 0 | 1 |
| Body temperature decreased | 1 | 0 |
| Body temperature increased | 0 | 1 |
| Bradycardia | 3 | 1 |
| Breath sounds abnormal | 0 | 1 |
| Cardiac murmur | 1 | 2 |
| Dyspnoea | 40 | 27 |
| Dyspnoea exertional | 2 | 5 |
| Heart rate increased | 0 | 1 |
| Heart rate irregular | 1 | 0 |
| Hypertension | 26 | 70 |
| Hypotension | 15 | 7 |
| Hyperpyrexia | 1 | 0 |
| Orthostatic hypotension | 2 | 1 |
| Palpitations | 12 | 15 |
| Pyrexia | 66 | 55 |
| Tachycardia | 7 | 7 |
| Weight decreased | 29 | 23 |
| Weight increased | 13 | 10 |
| White coat hypertension | 0 | 1 |
Percentage of participants with at least one occurrence of treatment-related lymphocytosis defined as an elevation in ALC of \>= 50% compared with baseline and a postbaseline assessment of \> 5000/μL in the peripheral blood are reported.
| Percentage of participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Percentage of Participants With Lymphocytosis | 72.5 (66.7 to 77.7) | 74.3 (68.6 to 79.5) |
Number of participants with ECG abnormality at baseline are reported.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Abnormal, not clinically significant | 86 | 98 |
| Abnormal, clinically significant | 4 | 1 |
The ECOG performance status assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=death. Number of participants with shift from baseline (Days -28 to -1) to worst Grade 3 and 4 in ECOG performance status are reported.
| Participants | Acalabrutinib | Ibrutinib |
|---|---|---|
| Baseline=0; Postbaseline=3 | 0 | 1 |
| Baseline=1; Postbaseline=3 | 3 | 5 |
| Baseline=2; Postbaseline=3 | 4 | 1 |
| Baseline=0; Postbaseline=4 | 0 | 0 |
| Baseline=1; Postbaseline=4 | 0 | 0 |
| Baseline=2; Postbaseline=4 | 0 | 0 |
Collected over Day 1 through 83.5 months (maximum observed duration).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib | 89/266 (33.5%) | 161/266 (60.5%) | 251/266 (94.4%) |
| Ibrutinib | 106/263 (40.3%) | 177/263 (67.3%) | 251/263 (95.4%) |
| Event | Acalabrutinib | Ibrutinib |
|---|---|---|
| PneumoniaInfections and infestations | 33/266 | 30/263 |
| Atrial fibrillationCardiac disorders | 8/266 | 16/263 |
| COVID-19Infections and infestations | 15/266 | 14/263 |
| AnaemiaBlood and lymphatic system disorders | 15/266 | 13/263 |
| PyrexiaGeneral disorders | 11/266 | 6/263 |
| SepsisInfections and infestations | 5/266 | 7/263 |
| Urinary tract infectionInfections and infestations | 3/266 | 7/263 |
| Cardiac failureCardiac disorders | 4/266 | 6/263 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/266 | 6/263 |
| Acute kidney injuryRenal and urinary disorders | 2/266 | 6/263 |
| Event | Acalabrutinib | Ibrutinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 93/266 | 122/263 |
| HeadacheNervous system disorders | 92/266 | 56/263 |
| CoughRespiratory, thoracic and mediastinal disorders | 79/266 | 60/263 |
| Upper respiratory tract infectionInfections and infestations | 73/266 | 65/263 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 55/266 | 70/263 |
| HypertensionVascular disorders | 26/266 | 70/263 |
| NeutropeniaBlood and lymphatic system disorders | 56/266 | 65/263 |
| FatigueGeneral disorders | 62/266 | 48/263 |
| PyrexiaGeneral disorders | 61/266 | 50/263 |
| AnaemiaBlood and lymphatic system disorders | 53/266 | 48/263 |
Intent-to-treat (ITT) population included all participants randomized and were analyzed according to the arm to which they were randomly assigned.
| Age, Continuous(Years) | Acalabrutinib | Ibrutinib | Total |
|---|---|---|---|
| Age (years) | 65.5 ± 9.3 | 65.3 ± 9.6 | 65.4 ± 9.4 |
| Sex: Female, Male(Participants) | Acalabrutinib | Ibrutinib | Total |
|---|---|---|---|
| Sex — Female | 83 | 71 | 154 |
| Sex — Male | 185 | 194 | 379 |
| Ethnicity (NIH/OMB)(Participants) | Acalabrutinib | Ibrutinib | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 5 | 13 |
| Not Hispanic or Latino | 235 | 237 | 472 |
| Unknown or Not Reported | 25 | 23 | 48 |
| Race (NIH/OMB)(Participants) | Acalabrutinib | Ibrutinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 8 | 13 |
| White | 257 | 245 | 502 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 10 | 15 |
Showing the first 100 of 130 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2015 to primary completion in Sep 2020, 61 months.
Results were first posted in Jan 2022, 1 year 4 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 61 months is above that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →